Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26667232 | 0.92 | MEN1 (0.52) | MEN1KMT2AGAACA1CA2 | |
| SCHEMBL15745584 | 0.92 | MEN1 (0.52) | MEN1KMT2AGAACA1CA2 | |
| SCHEMBL24580520 | 0.86 | MEN1 (0.63) | MEN1KMT2AGAACA1CA2 | |
| SCHEMBL4887762 | 0.85 | MEN1 (0.61) | MEN1KMT2AGAACA1CA2 | |
| SCHEMBL4056521 | 0.83 | MEN1 (0.49) | MEN1KMT2AGAACA1CA2 | |
| SCHEMBL5329057 | 0.81 | MAPT (0.59) | MAPT | |
| SCHEMBL5329053 | 0.81 | MAPT (0.59) | MAPT | |
| SCHEMBL12179560 | 0.81 | TDP1 (0.58) | MEN1KMT2AGAACA1CA2 | |
| SCHEMBL13702218 | 0.80 | MEN1 (0.58) | MEN1KMT2AGAACA1CA2 | |
| SCHEMBL13702219 | 0.80 | MEN1 (0.58) | MEN1KMT2AGAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000964-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | AJINOMOTO CO., INC. (JP) | 2024-01-04 | — | — | US | disclosed |
| EP-4279502-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED THEREFROM | AJINOMOTO CO., INC. (JP) | 2023-11-22 | — | — | EP | disclosed |
| CN-116761819-A | Compounds or salts thereof, and antibodies derived therefrom | 味之素株式会社 | 2023-09-15 | — | — | CN | disclosed |
| WO-2009026701-A1 | SIRTUIN INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000964-A1 | COMPOUND OR SALT THEREOF, AND ANTIBODY OBTAINED BY USING THE SAME | SSB, CTH, SCLY | MEN1 2419/4885KMT2A 991/4885GAA 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.